Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALTNASDAQ:CYANNASDAQ:KODNYSE:MRK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$4.43-6.9%$5.69$2.90▼$11.16$386.07M0.473.33 million shs6.12 million shsCYANCyanotech$0.41+14.0%$3.01$2.37▼$6.29$2.94M-0.113,483 shs200 shsKODKodiak Sciences$3.71-6.1%$3.84$1.92▼$11.60$208.42M2.28344,374 shs178,424 shsMRKMerck & Co., Inc.$80.890.0%$79.15$73.31▼$129.93$203.22B0.3913.24 million shs15.77 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-6.93%+14.47%-21.17%+20.71%-33.08%CYANCyanotech0.00%-10.00%-10.00%+17.88%-9.73%KODKodiak Sciences-6.31%-0.54%-12.09%+80.10%+57.87%MRKMerck & Co., Inc.-0.10%+2.15%+2.46%+2.69%-36.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALTAltimmune2.2136 of 5 stars3.51.00.00.02.41.70.6CYANCyanotechN/AN/AN/AN/AN/AN/AN/AN/AKODKodiak Sciences4.1146 of 5 stars3.04.00.04.61.13.30.0MRKMerck & Co., Inc.4.9961 of 5 stars3.23.05.04.23.02.53.8Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 3.00Buy$19.00328.89% UpsideCYANCyanotech 0.00N/AN/AN/AKODKodiak Sciences 2.00Hold$9.00142.59% UpsideMRKMerck & Co., Inc. 2.43Hold$109.1934.98% UpsideCurrent Analyst Ratings BreakdownLatest ALT, MRK, KOD, and CYAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/27/2025ALTAltimmuneWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform6/27/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.005/20/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Cautious5/14/2025MRKMerck & Co., Inc.CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$115.00 ➝ $84.004/22/2025MRKMerck & Co., Inc.Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$85.004/17/2025MRKMerck & Co., Inc.GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.00 ➝ $115.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K17,965.87N/AN/A$1.74 per share2.55CYANCyanotech$23.07M0.13N/AN/A$1.33 per share0.31KODKodiak SciencesN/AN/AN/AN/A$2.86 per shareN/AMRKMerck & Co., Inc.$64.17B3.17$9.46 per share8.55$18.33 per share4.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.26N/AN/AN/A-451,200.00%-65.44%-58.43%8/6/2025 (Estimated)CYANCyanotech-$5.27M-$0.66N/A∞N/A-19.50%-44.71%-19.12%N/AKODKodiak Sciences-$176.21M-$3.63N/AN/AN/AN/A-115.71%-54.17%8/13/2025 (Estimated)MRKMerck & Co., Inc.$17.12B$6.8711.778.170.8427.27%43.23%17.11%7/29/2025 (Estimated)Latest ALT, MRK, KOD, and CYAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/29/2025Q2 2025MRKMerck & Co., Inc.$2.03N/AN/AN/A$15.92 billionN/A5/14/2025Q1 2025KODKodiak Sciences-$0.89-$1.09-$0.20-$1.09N/AN/A5/13/2025Q1 2025ALTAltimmune-$0.35-$0.26+$0.09-$0.26$0.00 million$0.01 million4/24/2025Q1 2025MRKMerck & Co., Inc.$2.16$2.22+$0.06$2.01$15.59 billion$15.53 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/ACYANCyanotechN/AN/AN/AN/AN/AKODKodiak SciencesN/AN/AN/AN/AN/AMRKMerck & Co., Inc.$3.244.01%N/A47.16%14 YearsLatest ALT, MRK, KOD, and CYAN DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/27/2025MRKMerck & Co., Inc.quarterly$0.814.18%6/16/20256/16/20257/8/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmuneN/A15.8515.85CYANCyanotech0.111.060.28KODKodiak SciencesN/A4.624.62MRKMerck & Co., Inc.0.691.411.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%CYANCyanotech24.40%KODKodiak Sciences89.06%MRKMerck & Co., Inc.76.07%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.10%CYANCyanotech29.10%KODKodiak Sciences45.90%MRKMerck & Co., Inc.0.09%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5081.11 million77.78 millionOptionableCYANCyanotech957.16 million5.07 millionNot OptionableKODKodiak Sciences9052.76 million28.55 millionOptionableMRKMerck & Co., Inc.75,0002.51 billion2.51 billionOptionableALT, MRK, KOD, and CYAN HeadlinesRecent News About These CompaniesMerck & Co.: A Pharma Titan At A DiscountJuly 7 at 1:12 PM | seekingalpha.comChina Universal Asset Management Co. Ltd. Raises Stock Holdings in Merck & Co., Inc. (NYSE:MRK)July 7 at 8:49 AM | marketbeat.comAlpha Cubed Investments LLC Sells 161,076 Shares of Merck & Co., Inc. (NYSE:MRK)July 7 at 8:31 AM | marketbeat.comGibraltar Capital Management Inc. Purchases 20,833 Shares of Merck & Co., Inc. (NYSE:MRK)July 7 at 8:20 AM | marketbeat.comCrossmark Global Holdings Inc. Grows Stake in Merck & Co., Inc. (NYSE:MRK)July 7 at 7:44 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Acquired by Financial Counselors Inc.July 7 at 6:48 AM | marketbeat.comRaleigh Capital Management Inc. Sells 6,614 Shares of Merck & Co., Inc. (NYSE:MRK)July 7 at 6:48 AM | marketbeat.comTD Private Client Wealth LLC Purchases 9,258 Shares of Merck & Co., Inc. (NYSE:MRK)July 7 at 6:22 AM | marketbeat.comOLD Republic International Corp Buys 5,500 Shares of Merck & Co., Inc. (NYSE:MRK)July 7 at 6:21 AM | marketbeat.comRoffman Miller Associates Inc. PA Acquires 5,792 Shares of Merck & Co., Inc. (NYSE:MRK)July 7 at 6:10 AM | marketbeat.comMerck Mercuriadis plots return with new Hipgnosis venture after market reboundJuly 7 at 3:01 AM | proactiveinvestors.co.ukMerck & Co (MRK) Announces the Approval of ENFLONSIAJuly 6 at 6:22 PM | msn.comFDA Grants Priority Review for Merck & Co’s (MRK) WINREVAIRJuly 6 at 6:22 PM | msn.comMerck & Co., Inc. (NYSE:MRK) Shares Bought by Hexagon Capital Partners LLCJuly 6 at 9:47 AM | marketbeat.comChilton Capital Management LLC Sells 47,926 Shares of Merck & Co., Inc. (NYSE:MRK)July 6 at 9:18 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Sold by Investor s Fiduciary Advisor Network LLCJuly 6 at 9:18 AM | marketbeat.comMerck & Co., Inc. (NYSE:MRK) Shares Purchased by Argentarii LLCJuly 6 at 8:27 AM | marketbeat.comMcGlone Suttner Wealth Management Inc. Raises Position in Merck & Co., Inc. (NYSE:MRK)July 6 at 7:56 AM | marketbeat.comVickerman Investment Advisors Inc. Grows Holdings in Merck & Co., Inc. (NYSE:MRK)July 6 at 7:26 AM | marketbeat.comCore Alternative Capital Trims Stock Holdings in Merck & Co., Inc. (NYSE:MRK)July 6 at 7:26 AM | marketbeat.comStrategic Blueprint LLC Trims Stake in Merck & Co., Inc. (NYSE:MRK)July 6 at 6:15 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 AI Infrastructure Stocks With Strong Growth, Not HypeBy Chris Markoch | June 26, 2025View 3 AI Infrastructure Stocks With Strong Growth, Not HypeTop 3 Silver Picks to Watch as Bull Market Gains SteamBy Chris Markoch | June 18, 2025View Top 3 Silver Picks to Watch as Bull Market Gains SteamUnitedHealth Stock Dips: Is This a Value Buy Opportunity?By Jeffrey Neal Johnson | June 13, 2025View UnitedHealth Stock Dips: Is This a Value Buy Opportunity?Why Smart Money Just Bought $1.3B of Altria StockBy Gabriel Osorio-Mazilli | June 10, 2025View Why Smart Money Just Bought $1.3B of Altria StockForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffALT, MRK, KOD, and CYAN Company DescriptionsAltimmune NASDAQ:ALT$4.43 -0.33 (-6.93%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$4.43 +0.00 (+0.02%) As of 07/7/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Cyanotech NASDAQ:CYANCyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.Kodiak Sciences NASDAQ:KOD$3.71 -0.24 (-6.08%) Closing price 07/7/2025 04:00 PM EasternExtended Trading$3.82 +0.12 (+3.10%) As of 07/7/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Merck & Co., Inc. NYSE:MRK$80.89 -0.04 (-0.05%) Closing price 07/7/2025 03:59 PM EasternExtended Trading$81.05 +0.16 (+0.20%) As of 07/7/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
